Abiopharma

🔍 Lee Jennifer Kayden (Executive)

Company: RHYTHM PHARMACEUTICALS, INC. (RYTM)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 35,000 shares of Common Stock at $24.29 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 54,233.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 21,601 shares of Common Stock at $6.8 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: 0 | shares_owned_after: 75,834.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 75,834 shares of Common Stock at $117.3818 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 35,000 shares of Stock Options (Right to Buy) at $24.29 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2030-11-09 | equity_swap_involved: 0 | shares_owned_after: 36,283.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 21,601 shares of Stock Options (Right to Buy) at $6.8 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2032-02-08 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: The exercises and sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2026.
• F2: The stock options were granted on November 9, 2020. 25% of the shares subject to the option vested and become exercisable on November 9, 2021 and the remaining 75% of the shares subject to the option vested and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
• F3: The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.